期刊
ACTA PHARMACOLOGICA SINICA
卷 32, 期 12, 页码 1433-1445出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/aps.2011.140
关键词
lithium; valproate; lamotrigine; stroke; brain ischemia; glycogen synthase kinase-3; histone deacetylase; apoptosis; neurogenesis; angiogenesis
资金
- Hsu family gift fund
- National Institute of Mental Health (NIMH), National Institutes of Health
The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder. However, accumulating evidence suggests that these drugs have broad neuroprotective properties and may therefore be promising therapeutic agents for the treatment of neurodegenerative diseases, including stroke. Lithium, valproate and lamotrigine exert protective effects in diverse experimental stroke models by acting on their respective primary targets, ie, glycogen synthase kinase-3, histone deacetylases and voltage-gated sodium channels, respectively. This article reviews the most recent findings regarding the underlying mechanisms of these phenomena, which will pave the way for clinical investigations that use mood stabilizers to treat stroke. We also propose several future research avenues that may extend our understanding of the benefits of lithium, valproate and lamotrigine in improving stroke outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据